Paper16322467
The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth.
Kertesz N and 6 others. Blood, 2006. Cited by 138 papers, by iCite.
Cite this record
ConductScience Library. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Papers, record 16322467. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16322467
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Angiogenesis Modulating Agents | Major topic |
| Ephrin-B2 | Major topic |
| Neoplasms | Major topic |
| Peptide Fragments | Major topic |
| Receptor, EphB4 | Major topic |
| Angiogenesis Inhibitors | |
| Animals | |
| Cell Adhesion | |
| Cell Line, Tumor | |
| Cell Movement | |
| Cell Proliferation | |
| Cells, Cultured | |
| Endothelium, Vascular | |
| Growth Inhibitors | |
| Humans | |
| Mice | |
| Neoplasms, Experimental | |
| Neovascularization, Pathologic | |
| Protein Binding | |
| Solubility |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01CA79218 | NCI NIH HHS | United States | R01CA079218 | PubMed and NIH |
Source NIH RePORTER
References45
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11972959 | Ephrins are not only unattractive. | Trends Neurosci | 2002 | https://conductscience.org/library/papers/11972959 | PubMed |
| 2 | 9685371 | Distinct subdomains of the EphA3 receptor mediate ligand binding and receptor dimerization. | J Biol Chem | 1998 | https://conductscience.org/library/papers/9685371 | PubMed |
| 3 | 7621826 | Membrane-bound LERK2 ligand can signal through three different Eph-related receptor tyrosine kinases. | EMBO J | 1995 | https://conductscience.org/library/papers/7621826 | PubMed |
| 4 | 10630644 | Growth factor signaling pathways in vascular development. | Oncogene | 1999 | https://conductscience.org/library/papers/10630644 | PubMed |
| 5 | 11754836 | The receptor tyrosine kinase EphB2 regulates NMDA-dependent synaptic function. | Neuron | 2001 | https://conductscience.org/library/papers/11754836 | PubMed |
| 6 | 11799227 | Neurobiology. Learning more about NMDA receptor regulation. | Science | 2002 | https://conductscience.org/library/papers/11799227 | PubMed |
| 7 | 8761303 | Characterization of a ligand for receptor protein-tyrosine kinase HTK expressed in immature hematopoietic cells. | Oncogene | 1996 | https://conductscience.org/library/papers/8761303 | PubMed |
| 8 | 9990854 | Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. | Genes Dev | 1999 | https://conductscience.org/library/papers/9990854 | PubMed |
| 9 | 11001067 | Vascular-specific growth factors and blood vessel formation. | Nature | 2000 | https://conductscience.org/library/papers/11001067 | PubMed |
| 10 | 12594815 | Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. | Int J Cancer | 2003 | https://conductscience.org/library/papers/12594815 | PubMed |
| 11 | 11256076 | Multiple roles of EPH receptors and ephrins in neural development. | Nat Rev Neurosci | 2001 | https://conductscience.org/library/papers/11256076 | PubMed |
| 12 | 10403252 | Eph receptors and ephrins restrict cell intermingling and communication. | Nature | 1999 | https://conductscience.org/library/papers/10403252 | PubMed |
| 13 | 11163240 | The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration. | Cell | 2001 | https://conductscience.org/library/papers/11163240 | PubMed |
| 14 | 10688823 | Vasculogenesis in the day 6.5 to 9.5 mouse embryo. | Blood | 2000 | https://conductscience.org/library/papers/10688823 | PubMed |
| 15 | 8689573 | Vasculogenesis. | Annu Rev Cell Dev Biol | 1995 | https://conductscience.org/library/papers/8689573 | PubMed |
| 16 | 12134157 | EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas). | Nat Cell Biol | 2002 | https://conductscience.org/library/papers/12134157 | PubMed |
| 17 | 12185851 | Ephrins in reverse, park and drive. | Trends Cell Biol | 2002 | https://conductscience.org/library/papers/12185851 | PubMed |
| 18 | 11750881 | The ephrins and Eph receptors in angiogenesis. | Cytokine Growth Factor Rev | 2002 | https://conductscience.org/library/papers/11750881 | PubMed |
| 19 | 12118063 | Ephrin-B1 transduces signals to activate integrin-mediated migration, attachment and angiogenesis. | J Cell Sci | 2002 | https://conductscience.org/library/papers/12118063 | PubMed |
| 20 | 10197531 | EphrinB ligands recruit GRIP family PDZ adaptor proteins into raft membrane microdomains. | Neuron | 1999 | https://conductscience.org/library/papers/10197531 | PubMed |
Cited by77
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 138 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42698964 | Macrophages Drive Ferroptosis Resistance after Radiotherapy. | Cancer Commun (Lond) | 2026 | https://conductscience.org/library/papers/42698964 | PubMed |
| 41641748 | Prototyping Minimal Extracellular Vesicle Mimetics Using Cell-Free Synthesis. | ACS Nano | 2026 | https://conductscience.org/library/papers/41641748 | PubMed |
| 40044981 | EphB4-ephrin-B2 are targets in castration resistant prostate cancer. | Br J Cancer | 2025 | https://conductscience.org/library/papers/40044981 | PubMed |
| 39361504 | Overview of mechanism of electroacupuncture pretreatment for prevention and treatment of cardiovascular and cerebrovascular diseases. | CNS Neurosci Ther | 2024 | https://conductscience.org/library/papers/39361504 | PubMed |
| 38985143 | Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma. | Oncotarget | 2024 | https://conductscience.org/library/papers/38985143 | PubMed |
| 38612645 | The Clinical Relevance of the EPH/Ephrin Signaling Pathway in Pediatric Solid and Hematologic Malignancies. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38612645 | PubMed |
| 38540132 | Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand? | Biomedicines | 2024 | https://conductscience.org/library/papers/38540132 | PubMed |
| 38231476 | Inhibition of Ephrin B2 Reverse Signaling Abolishes Multiple Myeloma Pathogenesis. | Cancer Res | 2024 | https://conductscience.org/library/papers/38231476 | PubMed |
| 38097539 | Aberrant epithelial cell interaction promotes esophageal squamous-cell carcinoma development and progression. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/38097539 | PubMed |
| 37996538 | Eph receptors and ephrins in cancer progression. | Nat Rev Cancer | 2024 | https://conductscience.org/library/papers/37996538 | PubMed |
| 37982352 | Dihydroartemisinin inhibits melanoma migration and metastasis by affecting angiogenesis. | Phytother Res | 2025 | https://conductscience.org/library/papers/37982352 | PubMed |
| 37945764 | Progress in systemic therapy for advanced-stage urothelial carcinoma. | Nat Rev Clin Oncol | 2024 | https://conductscience.org/library/papers/37945764 | PubMed |
| 37823054 | Over-expression by degradation rescue of RTKs via cancer-secreted autocrine growth factors: a Phospho-degron-driven actionable layer of post-translational regulation? | Front Oncol | 2023 | https://conductscience.org/library/papers/37823054 | PubMed |
| 37575160 | EphrinB2: Expression of a novel potential target in renal cell carcinoma. | Indian J Urol | 2023 | https://conductscience.org/library/papers/37575160 | PubMed |
| 35725568 | EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment. | Nat Commun | 2022 | https://conductscience.org/library/papers/35725568 | PubMed |
| 34298619 | Tyrosine Phosphoproteomics of Patient-Derived Xenografts Reveals Ephrin Type-B Receptor 4 Tyrosine Kinase as a Therapeutic Target in Pancreatic Cancer. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34298619 | PubMed |
| 33816783 | Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma. | Mol Ther Oncolytics | 2021 | https://conductscience.org/library/papers/33816783 | PubMed |
| 33614496 | Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature. | Front Oncol | 2020 | https://conductscience.org/library/papers/33614496 | PubMed |
| 32488576 | The critical role of the interplays of EphrinB2/EphB4 and VEGF in the induction of angiogenesis. | Mol Biol Rep | 2020 | https://conductscience.org/library/papers/32488576 | PubMed |
| 32362422 | EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy. | Pathol Res Pract | 2020 | https://conductscience.org/library/papers/32362422 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EPHB4 | 2050 | PubTator's text mining | https://conductscience.org/library/genes/2050 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16322467
GET https://conductscience.org/api/papers/v1/16322467/references?page=2